TISIDB

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Nucleus. Note=Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.
Domain	PF00439 Bromodomain PF09030 Creb binding PF06001 Domain of Unknown Function (DUF902) PF08214 Histone acetylation protein PF02172 KIX domain PF02135 TAZ zinc finger PF00569 Zinc finger
Function	Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902).

> Gene Ontology [ TOP ]
Biological Process	GO:0001666 response to hypoxia GO:0001819 positive regulation of cytokine production GO:0002218 activation of innate immune response GO:0002220 innate immune response activating cell surface receptor signaling pathway GO:0002223 stimulatory C-type lectin receptor signaling pathway GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006352 DNA-templated transcription, initiation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0006473 protein acetylation GO:0006474 N-terminal protein amino acid acetylation GO:0006475 internal protein amino acid acetylation GO:0007219 Notch signaling pathway GO:0007224 smoothened signaling pathway GO:0008589 regulation of smoothened signaling pathway GO:0009266 response to temperature stimulus GO:0009314 response to radiation GO:0009408 response to heat GO:0009411 response to UV GO:0009416 response to light stimulus GO:0016570 histone modification GO:0016573 histone acetylation GO:0018076 N-terminal peptidyl-lysine acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0030326 embryonic limb morphogenesis GO:0031349 positive regulation of defense response GO:0031365 N-terminal protein amino acid modification GO:0032479 regulation of type I interferon production GO:0032481 positive regulation of type I interferon production GO:0032606 type I interferon production GO:0034605 cellular response to heat GO:0034644 cellular response to UV GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0042733 embryonic digit morphogenesis GO:0043543 protein acylation GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress GO:0043620 regulation of DNA-templated transcription in response to stress GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0048511 rhythmic process GO:0048736 appendage development GO:0060173 limb development GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0070482 response to oxygen levels GO:0071214 cellular response to abiotic stimulus GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:1900034 regulation of cellular response to heat GO:1904837 beta-catenin-TCF complex assembly
Molecular Function	GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001085 RNA polymerase II transcription factor binding GO:0001102 RNA polymerase II activating transcription factor binding GO:0001104 RNA polymerase II transcription cofactor activity GO:0001105 RNA polymerase II transcription coactivator activity GO:0001159 core promoter proximal region DNA binding GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0002039 p53 binding GO:0003682 chromatin binding GO:0003684 damaged DNA binding GO:0003713 transcription coactivator activity GO:0004402 histone acetyltransferase activity GO:0008080 N-acetyltransferase activity GO:0008134 transcription factor binding GO:0016407 acetyltransferase activity GO:0016410 N-acyltransferase activity GO:0016746 transferase activity, transferring acyl groups GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups GO:0033613 activating transcription factor binding GO:0034212 peptide N-acetyltransferase activity GO:0043425 bHLH transcription factor binding GO:0043426 MRF binding GO:0061733 peptide-lysine-N-acetyltransferase activity GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component	GO:0000123 histone acetyltransferase complex GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0016604 nuclear body GO:0031248 protein acetyltransferase complex GO:0044454 nuclear chromosome part GO:1902493 acetyltransferase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04024 cAMP signaling pathway hsa04066 HIF-1 signaling pathway hsa04068 FoxO signaling pathway hsa04110 Cell cycle hsa04310 Wnt signaling pathway hsa04330 Notch signaling pathway hsa04350 TGF-beta signaling pathway hsa04520 Adherens junction hsa04630 Jak-STAT signaling pathway hsa04720 Long-term potentiation hsa04916 Melanogenesis hsa04919 Thyroid hormone signaling pathway hsa04922 Glucagon signaling pathway
Reactome	R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-2426168: Activation of gene expression by SREBF (SREBP) R-HSA-8866907: Activation of the TFAP2 (AP-2) family of transcription factors R-HSA-3371568: Attenuation phase R-HSA-1368108: BMAL1 R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5621575: CD209 (DC-SIGN) signaling R-HSA-3371556: Cellular response to heat stress R-HSA-2262749: Cellular response to hypoxia R-HSA-2262752: Cellular responses to stress R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-400253: Circadian Clock R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism R-HSA-201722: Formation of the beta-catenin R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-3214847: HATs acetylate histones R-HSA-3371571: HSF1-dependent transactivation R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-3134973: LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1592230: Mitochondrial biogenesis R-HSA-157052: NICD traffics to nucleus R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription R-HSA-350054: Notch-HLH transcription pathway R-HSA-1852241: Organelle biogenesis and maintenance R-HSA-1989781: PPARA activates gene expression R-HSA-1912422: Pre-NOTCH Expression and Processing R-HSA-1912408: Pre-NOTCH Transcription and Translation R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways R-HSA-1368082: RORA activates gene expression R-HSA-1234174: Regulation of Hypoxia-inducible Factor (HIF) by oxygen R-HSA-1655829: Regulation of cholesterol biosynthesis by SREBP (SREBF) R-HSA-1234158: Regulation of gene expression by Hypoxia-inducible Factor R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) R-HSA-162582: Signal Transduction R-HSA-157118: Signaling by NOTCH R-HSA-1980143: Signaling by NOTCH1 R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer R-HSA-2644603: Signaling by NOTCH1 in Cancer R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes R-HSA-6803204: TP53 Regulates Transcription of Genes Involved in Cytochrome C Release R-HSA-918233: TRAF3-dependent IRF activation pathway R-HSA-933541: TRAF6 mediated IRF7 activation R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-2151201: Transcriptional activation of mitochondrial biogenesis R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors R-HSA-381340: Transcriptional regulation of white adipocyte differentiation R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04024 cAMP signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04110 Cell cycle
hsa04310 Wnt signaling pathway
hsa04330 Notch signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04520 Adherens junction
hsa04630 Jak-STAT signaling pathway
hsa04720 Long-term potentiation
hsa04916 Melanogenesis
hsa04919 Thyroid hormone signaling pathway
hsa04922 Glucagon signaling pathway

Reactome

R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-2426168: Activation of gene expression by SREBF (SREBP)
R-HSA-8866907: Activation of the TFAP2 (AP-2) family of transcription factors
R-HSA-3371568: Attenuation phase
R-HSA-1368108: BMAL1
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621575: CD209 (DC-SIGN) signaling
R-HSA-3371556: Cellular response to heat stress
R-HSA-2262749: Cellular response to hypoxia
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-400253: Circadian Clock
R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-201722: Formation of the beta-catenin
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-3214847: HATs acetylate histones
R-HSA-3371571: HSF1-dependent transactivation
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-3134973: LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1592230: Mitochondrial biogenesis
R-HSA-157052: NICD traffics to nucleus
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-350054: Notch-HLH transcription pathway
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-1989781: PPARA activates gene expression
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912408: Pre-NOTCH Transcription and Translation
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1368082: RORA activates gene expression
R-HSA-1234174: Regulation of Hypoxia-inducible Factor (HIF) by oxygen
R-HSA-1655829: Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-1234158: Regulation of gene expression by Hypoxia-inducible Factor
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes
R-HSA-6803204: TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
R-HSA-918233: TRAF3-dependent IRF activation pathway
R-HSA-933541: TRAF6 mediated IRF7 activation
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-2151201: Transcriptional activation of mitochondrial biogenesis
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CREBBP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CREBBP and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25713363	Follicular Lymphoma	Promote immunity	These observations therefore implicate CREBBP mutation as an early event in FL evolution that contributes to immune evasion via decreased antigen presentation.
27733359	Lymphoma	Promote immunity	Hence, CREBBP loss-of-function contributes to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas.
28831000	Diffuse Large B-Cell Lymphoma	Promote immunity	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. CREBBP-mutant DLBCL clones exhibited reduced histone H3 acetylation, expressed significantly less MHCII, and grew faster than wild-type clones in s.c.

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CREBBP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CREBBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.106	0.584
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.132	0.931
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.085	0.941
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.02	0.963
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.353	0.903
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.496	0.897
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.168	0.649
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.115	0.947
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.212	0.913
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.05	0.965
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.335	0.837
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.126	0.0115

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CREBBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	5.9	8.4	0.576
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	7.1	17.9	0.405
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	9.6	-5.9	0.679
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	11.9	-8.2	0.426
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	0	50	0.109
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CREBBP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CREBBP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CREBBP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CREBBP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CREBBP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CREBBP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CREBBP
Name	CREB binding protein
Aliases	KAT3A; RSTS; Rubinstein-Taybi syndrome; CREB-binding protein
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CREBBP collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CREBBP.

ID	Name	Drug Type	Targets	#Targets
DB08655	9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE	Small Molecule	CREBBP	1

Browse CREBBP